Targeting the prostaglandin (PG) pathway is potentially a critical intervention for the
prevention and treatment of cancer. Central to PG biosynthesis are two isoforms of …

Background Cyclooxygenase (COX) is the rate-limiting enzyme that catalyzes the formation
of prostaglandins. The inducible isoform of COX (COX-2) is highly expressed in aggressive …

In squamous cell carcinoma, the levels of nitric oxide (NO) derived from inducible NO
synthase (iNOS) and prostaglandin E2 (PGE2) derived from cyclooxygenase‐2 (COX‐2) …

Cyclooxygenase-2 (COX-2)-mediated prostaglandin synthesis has recently been implicated
in human cholangiocarcinogenesis. This study was designed to examine the mechanisms …

It is widely accepted that alterations to cyclooxygenase-2 (COX-2) expression and the
abundance of its enzymatic product prostaglandin E 2 (PGE 2) have key roles in influencing …

Abstract Prostaglandin E2 (PGE2) receptor 2 subtype (EP2), which is a metabolite of
arachidonic acid that binds with and regulates cellular responses to PGE2, is associated …

Abstract Overexpression of cyclooxygenase‐2 (COX‐2) and elevation of its derivative
prostaglandin E2 (PGE2) are implicated in human esophageal squamous cell carcinoma …

Background: Cyclooxygenase-2 (COX-2) over-expression and subsequent prostaglandin E2
(PGE2) production are frequently associated with human non-small-cell lung cancer …

Antiangiogenic agents that block vascular endothelial growth factor (VEGF) signaling are
important components of current cancer treatment modalities but are limited by alternative ill …

Background The targeting of the immune system through immunotherapies to prevent tumor
tolerance and immune suppression are at the front lines of breast cancer treatment and …